{"id":"W2611548364","doi":"10.1056/nejmoa1606910","title":"Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis","year":2017,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1727,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University; Robarts Clinical Trials; Western University","funders":"Pfizer","keywords":"Tofacitinib; Ulcerative colitis; Medicine; Janus kinase inhibitor; Maintenance therapy; Induction therapy; Janus kinase; Colitis; Internal medicine; Gastroenterology; Chemotherapy; Receptor; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01712734440931054,"score_gpt":0.2945029057821552,"score_spread":0.2773755613728447,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}